Guardant Health(US:GH)2026-02-19 22:30Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281.3 million, representing a 39% year-over-year growth, while full-year revenue reached $982.0 million, a 33% increase year-over-year [7][28]. - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, and for the full year, it increased from 62% in 2024 to 66% [29][30]. - Adjusted EBITDA loss improved to $64.9 million in Q4 compared to $78.4 million in the prior year, and for the full year, the loss was $220.9 million versus $257.5 million in 2024 [31]. Business Line Data and Key Metrics Changes - Oncology revenue increased by 30% to $189.9 million in Q4, with approximately 79,000 tests conducted, reflecting a 38% volume growth [25][28]. - Screening revenue totaled $35.1 million from approximately 38,000 Shield tests in Q4, with an average selling price (ASP) of approximately $850 [27][30]. - Biopharma and data revenue grew 9% to $54.0 million, aligning with expectations [27]. Market Data and Key Metrics Changes - The company received Medicare coverage for colorectal cancer (CRC) surveillance in early 2025, which has positively impacted the adoption of Reveal [5]. - The Shield test has shown strong adherence rates of 93% among patients, significantly higher than traditional screening methods [18]. Company Strategy and Development Direction - The company aims to expand its multi-cancer detection capabilities through the Shield platform, which includes a new multi-cancer detection results report [21]. - Strategic partnerships with Quest Diagnostics and PathGroup are expected to enhance national reach and operational capabilities in 2026 [19][20]. - The acquisition of MetaCyte Diagnostics is anticipated to enhance the company's R&D capabilities and accelerate its multi-disease detection pipeline [32]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong growth in oncology, projecting a 25%-27% growth rate for oncology revenue in 2026, supported by volume growth of approximately 30% [33]. - The company expects to achieve free cash flow positivity for the core business in 2026, excluding screening, and aims for company-wide cash flow breakeven by the end of 2027 [32][36]. - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [42]. Other Important Information - The company has established a robust pipeline of ongoing companion diagnostics (CDx) programs, with 25 approvals to date across various regions [14]. - The company is focused on improving gross margins through ASP optimization and operational efficiencies, with expectations of non-GAAP gross margins in the range of 64%-65% for 2026 [36]. Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for patient monitoring and therapeutic decisions [40][42]. Question: How should we think about oncology growth throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal, which is anticipated to remain the fastest-growing product [46][48]. Question: What is the expected burn for Shield in 2026? - The company anticipates a similar burn level for screening as in 2025, around $220 million, while the rest of the business is expected to be free cash flow positive [50][52]. Question: What is the latest on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission progress in the second half of the year [58][59]. Question: Can you discuss the opt-in rate for MCED Shield and potential FDA submissions? - Management noted good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not provide specific numbers [76][78].